Mon, Mar 2, 2015, 1:13 AM EST - U.S. Markets open in 8 hrs 17 mins

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Dec 16, 2012 5:48 PM Flag

    Celestia Higano Bone Microenvironment Trial

    $$$$

    Sorry to be so slow...Yahoo has been giving me fits...
    Ernie, this is more of the same bone mets chat. Yahoo shut me out of our prior conv...

    The latest Celetia Higano Cabo trial - an intended exploration of the bone tumor micro-environment would seem to be one of the more important of the recent additions - at least wrt further understanding of Cabo's bone effect.

    "Official Title: A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
    Primary Outcome Measures:
    •Change in urinary N-telopeptide (uNTX) [ Time Frame: Baseline and 6 weeks ] [ Designated as safety issue: No ]
    Will be analyzed after log-transformation."

    It appears data for primary endpoint should be gathered 6 weeks following final patient recruitment and analyzed after log-transformation. What's that mean?
    Thanks for all your great replies, Ernie!

    GLTA

 
EXEL
2.930.000(0.00%)Feb 27 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.